Skip to main content
Top
Published in: BMC Hematology 1/2018

Open Access 01-12-2018 | Research article

The impact of helicobacter pylori eradication on platelet counts of adult patients with idiopathic thrombocytopenic purpura

Authors: Sara Aljarad, Ahmad Alhamid, Ahmad Sankari Tarabishi, Ameen Suliman, Ziad Aljarad

Published in: BMC Hematology | Issue 1/2018

Login to get access

Abstract

Background

Idiopathic (immune) thrombocytopenic purpura (ITP) is an acquired disorder characterized by autoantibodies against platelet membrane antigens. Several studies found an association between Helicobacter Pylori infection and the incidence of ITP. So far, It is still unclear whether H. pylori eradication will increase platelet counts in adult ITP patients. We conduct this study to investigate platelet recovery in ITP patients after H. pylori eradication.

Methods

This is a prospective study. The diagnostic criterion for Idiopathic thrombocytopenic purpura is: isolated thrombocytopenia, with no evidence of any underlying causes like drugs, TTP, SLE, hepatitis, HIV,CLL and… etc. We examined blood smears of all patients. We have diagnosed Helicobacter pylori infection by histological examination of several biopsies obtained from stomach and duodenum by esophagogastroduodenoscopy (EGD). If EGD was not applicable due to patient’s poor situation or platelet count, H.pylori infection was diagnosed by the positivity of serum antibodies or respiratory urease test. We treated infected patients with triple therapy (omeprazole 40 mg once daily, amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily) for 14 days. Uninfected patients did not receive any treatment. We did platelet quantification at the beginning of the study, at the end of the first month, at the end of the third month and at the end of the sixth month.

Results

This study involved 50 patients with chronic ITP, 29 males (58%) and 21 females (42%). Participants ages range between18 and 51 years (mean age = 28.60 years). We diagnosed H. pylori in 36 patients (72%), who were treated with triple therapy. At the end of the sixth month, 10 of them (27.77%) showed complete response, and 18 of them (50%) showed partial response. The 14 uninfected patients, who did not receive any treatment, did not show neither complete nor partial response. Patient sex and age were not associated with achieving response, while baseline platelet count and H.pylori infection did.

Conclusion

Helicobacter pylori eradication significantly increases platelet counts in adult ITP patients.
Literature
1.
go back to reference Terrell DR, Beebe LA, Neas BR, et al. Prevalence of primary immune thrombocytopenia in Oklahoma. Am J Hematol. 2012 Sep;87(9):848–52.CrossRef Terrell DR, Beebe LA, Neas BR, et al. Prevalence of primary immune thrombocytopenia in Oklahoma. Am J Hematol. 2012 Sep;87(9):848–52.CrossRef
2.
go back to reference Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children. Report from an international working group. Blood. 2009 Mar 12;113(11):2386–93.CrossRef Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children. Report from an international working group. Blood. 2009 Mar 12;113(11):2386–93.CrossRef
3.
go back to reference Kuhne T, Imbach P, Bolton Maggs PH, et al. Newly diagnosed ITP in the children an observational study. Lancet. 2001;358(9299):2122–5.CrossRef Kuhne T, Imbach P, Bolton Maggs PH, et al. Newly diagnosed ITP in the children an observational study. Lancet. 2001;358(9299):2122–5.CrossRef
4.
go back to reference Toltl LJ, Arnold DM. Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters. Br J Haematol. 2011 Jan;152(1):52–60.CrossRef Toltl LJ, Arnold DM. Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters. Br J Haematol. 2011 Jan;152(1):52–60.CrossRef
5.
go back to reference Franchini M, Veneri D. Helicobacter pylori –associated immune thrombocytopenia. Am J Hematology. 2012 Jul;38(5):463–8. Franchini M, Veneri D. Helicobacter pylori –associated immune thrombocytopenia. Am J Hematology. 2012 Jul;38(5):463–8.
6.
go back to reference Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011 Apr 21;117(16):4190–207.CrossRef Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011 Apr 21;117(16):4190–207.CrossRef
7.
go back to reference Cines DB. Blanchette . “immune thrombocytopenic purpura”. N Engl J Med. 2002;346(13):995–1008.CrossRef Cines DB. Blanchette . “immune thrombocytopenic purpura”. N Engl J Med. 2002;346(13):995–1008.CrossRef
8.
go back to reference Cines DB, Bussel JB (2005). how I treat idiopathic thrombocytopenic purpura (ITP). Blood 2012;120(5):960–969. Cines DB, Bussel JB (2005). how I treat idiopathic thrombocytopenic purpura (ITP). Blood 2012;120(5):960–969.
9.
go back to reference Tan HJ, Goh KL. Extragastrointestinal manifestations of helicobacter pylori infection: facts or myth? A critical review. J Dig Dis. 2012 Jul;13(7):342–9.CrossRef Tan HJ, Goh KL. Extragastrointestinal manifestations of helicobacter pylori infection: facts or myth? A critical review. J Dig Dis. 2012 Jul;13(7):342–9.CrossRef
10.
go back to reference Weiss AA. Helicobacter pylori treatment and eradication. In: Sands MD BE, editor. “MOUNT SINAI EXPERT GUIDES gastroenterology” textbook. 1st ed; 2015. p. 180–93. Weiss AA. Helicobacter pylori treatment and eradication. In: Sands MD BE, editor. “MOUNT SINAI EXPERT GUIDES gastroenterology” textbook. 1st ed; 2015. p. 180–93.
11.
go back to reference Campuzano-Maya G. Proof of an association between helicobacter pylori and idiopathic thrombocytopenic purpura in Latin America. Helicobacter. 2007 Jun;12(3):265–73.CrossRef Campuzano-Maya G. Proof of an association between helicobacter pylori and idiopathic thrombocytopenic purpura in Latin America. Helicobacter. 2007 Jun;12(3):265–73.CrossRef
12.
go back to reference Gerhard M, Rad R, Prinz C, Naumann M. Pathogenesis of helicobacter pylori infection. Helicobacter. 2002;7(Suppl 1):17–23.CrossRef Gerhard M, Rad R, Prinz C, Naumann M. Pathogenesis of helicobacter pylori infection. Helicobacter. 2002;7(Suppl 1):17–23.CrossRef
13.
14.
go back to reference Byrne MF, Kerrigan SW, Corcoran PA, et al. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology. 2003 Jun;124(7):1846–54.CrossRef Byrne MF, Kerrigan SW, Corcoran PA, et al. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology. 2003 Jun;124(7):1846–54.CrossRef
15.
go back to reference Stasi R, Rossi Z, Stipa E, Amadori S, Newland AC, Provan D. Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. Am J Med. 2005 April;118(4):414–9.CrossRef Stasi R, Rossi Z, Stipa E, Amadori S, Newland AC, Provan D. Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. Am J Med. 2005 April;118(4):414–9.CrossRef
Metadata
Title
The impact of helicobacter pylori eradication on platelet counts of adult patients with idiopathic thrombocytopenic purpura
Authors
Sara Aljarad
Ahmad Alhamid
Ahmad Sankari Tarabishi
Ameen Suliman
Ziad Aljarad
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Hematology / Issue 1/2018
Electronic ISSN: 2052-1839
DOI
https://doi.org/10.1186/s12878-018-0119-y

Other articles of this Issue 1/2018

BMC Hematology 1/2018 Go to the issue